Cancer Research

Published by: American Association for Cancer Research  

People

  1. Berger
    Berger
  2. Solit
    Solit
  3. Schram
    Schram
  4. Ladanyi
    Ladanyi
  5. Drilon
    Drilon
  6. Bandlamudi
    Bandlamudi
  7. Offit
    Offit
  8. Stadler
    Stadler
  9. Arcila
    Arcila
  10. Chandarlapaty
    Chandarlapaty

Groups

  1. Department of Medicine (37)
  2. Early Drug Development Service (37)
  3. Solid Tumor Oncology Division (37)
  4. GSK Faculty (24)
  5. Human Oncology and Pathogenesis Program (24)
  6. Department of Pathology and Laboratory Medicine (19)
  7. Sloan Kettering Institute Postdocs (16)
  8. Breast Medicine Service (15)
  9. Genitourinary Oncology Service (15)
  10. Gynecologic Medicine Service (15)
Search Within
  1. "Early Drug Development Service"
Formats
  1. Meeting Abstract (35)
  2. Journal Article (2)
Groups
  1. Department of Medicine (37)
  2. Early Drug Development Service (37)
  3. Solid Tumor Oncology Division (37)
  4. GSK Faculty (24)
  5. Human Oncology and Pathogenesis Program (24)
  6. Department of Pathology and Laboratory Medicine (19)

More Groups

People
  1. David Hyman (32)
  2. David Solit (14)
  3. Michael Berger (14)
  4. Alison Schram (13)
  5. Marc Ladanyi (12)
  6. Alexander Drilon (10)

More People

Years
  1. 2022 (2)
  2. 2021 (2)
  3. 2020 (6)
  4. 2019 (16)
  5. 2018 (5)
  6. 2017 (3)

More Years

Publishers
  1. American Association for Cancer Research (37)

Results (37)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations
    Meeting Abstract

    Yap, T. A.; Im, S. A.; Schram, A. M.; Sharp, A.; Balmana, J.; Baird, R. D.; Brown, J. S.; Schwaederle, M.; Pilling, E. A.; Moorthy, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • OncoKB, MSK's precision oncology knowledge base
    Meeting Abstract

    Suehnholz, S. P.; Nissan, M.; Zhang, H.; Kundra, R.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; Ladanyi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • The HER2xHER3 bi-specific antibody Zenocutuzumab is effective at blocking growth of tumors driven by NRG1 gene fusions
    Meeting Abstract

    Odintsov, I.; Khodos, I.; Espinosa-Cotton, M.; Lui, A. J.; Mattar, M.; Schram, A. M.; Schackmann, R. C.; Lammerts van Bueren, J.; Geuijen, C. A.; de Stanchina, E.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
    Meeting Abstract

    Rosen, E. Y.; Italiano, A.; Juric, D.; Reeves, J. A.; Dima, L.; Brega, N.; Drilon, A.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • The utility of plasma ctDNA for detection of KRAS G12C and other mutations in lung cancers
    Meeting Abstract

    Murciano-Goroff, Y. R.; Arbour, K. C.; Offin, M. D.; Tu, H. Y. Y.; Lebow, E. S.; Shaffer, T. S.; Bertucci, C.; Hosseini, S. A.; Garg, K.; Lim, L. P.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer
    Meeting Abstract

    Liu, B.; Ross, D. S.; Schram, A. M.; Razavi, P.; Lagana, S. M.; Zhang, Y.; Scaltriti, M.; Bromberg, J. F.; Ladanyi, M.; Hyman, D. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
    Meeting Abstract

    Cocco, E.; Lee, J. E.; Kannan, S.; Schram, A. M.; Won, H. H.; Shifman, S.; Kulick, A.; Baldino, L.; Toska, E.; Arena, S.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Oncologic therapy shapes the fitness landscape of clonal hematopoiesis
    Meeting Abstract

    Bolton, K. L.; Ptashkin, R. N.; Gao, T.; Braunstein, L.; Devlin, S. M.; Patel, M.; Berthon, A.; Syed, A.; Yabe, M.; Coombs, C.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT 'basket' trial
    Meeting Abstract

    Wildiers, H.; Boni, V.; Saura, C.; Oliveira, M.; Jhaveri, K.; Won, H.; Bidard, F. C.; Brufsky, A. M.; Burkard, M. E.; Cervantes, A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Capivasertib (AZD5363) in combination with fulvestrant in PTEN-mutant ER+ metastatic breast cancer
    Meeting Abstract

    Smyth, L. M.; Batist, G.; Meric-Bernstam, F.; Kabos, P.; Spanggaard, I.; Lluch, A.; Schram, A.; Varga, A.; Wong, A.; Ambrose, H.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save

    • Cancer Research – authorized name for:

    Name ISSN / ISBN Publisher
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 15387445 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association Tor Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 Unknown
    Cancer research 15387445 The Authors the American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 15387445 American Association for Cancer Research
    Cancer research 15387445 American Association for Cancer Research
    Cancer Research 00085472 Unknown
    Cancer Research 00085472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer research 15387445 Unknown
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 0008-5472 American Association for Cancer Research
    Cancer Research 00085472 American Association for Cancer
    Cancer Research 00085472 The Authors
    Cancer Research 00085472 The Authors the American Association for Cancer Research